Abstract
To complement the immunosuppressive regimens, at the time of lung transplantation or in the previous postoperative period, many centers are using as induction therapy the drug basiliximab which is an antibody antagonists of the Interleukin-2 receptor. It is known that the main cause of death in the first month after lung transplantation is infectious, coinciding with the same period of gr…